{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:01:22Z","timestamp":1793048482774,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM 139428"],"award-info":[{"award-number":["GM 139428"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM103447"],"award-info":[{"award-number":["P20GM103447"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cbi.2025.111597","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T19:08:58Z","timestamp":1749236938000},"page":"111597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The use of phosphotriesterase in the synthesis of enantiomerically pure ProTide prodrugs"],"prefix":"10.1016","volume":"418","author":[{"given":"Andrew N.","family":"Bigley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank M.","family":"Raushel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2025.111597_bib1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.1256739","article-title":"HIV epidemiology. The early spread and epidemic ignition of HIV-1 in human populations","volume":"346","author":"Faria","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.cbi.2025.111597_bib2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1080\/20477724.2015.1122852","article-title":"Middle East respiratory syndrome coronavirus (MERS-CoV): animal to human interaction","volume":"109","author":"Omrani","year":"2015","journal-title":"Pathog. Glob. Health"},{"key":"10.1016\/j.cbi.2025.111597_bib3","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa030781","article-title":"A novel coronavirus associated with severe acute respiratory syndrome","volume":"348","author":"Ksiazek","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cbi.2025.111597_bib4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cbi.2025.111597_bib5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.33073\/pjm-2020-044","article-title":"Hepatitis B virus: from diagnosis to treatment","volume":"69","author":"Guvenir","year":"2020","journal-title":"Pol. J. Microbiol."},{"key":"10.1016\/j.cbi.2025.111597_bib6","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/liv.14011","article-title":"Hepatitis C: is eradication possible?","volume":"39","author":"Lombardi","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.cbi.2025.111597_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2471\/BLT.19.237149","article-title":"Herpes simplex virus: global infection prevalence and incidence estimates, 2016","volume":"98","author":"James","year":"2020","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.cbi.2025.111597_bib8","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.cbi.2025.111597_bib9","first-page":"165","article-title":"History and progress of antiviral drugs: from acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C","volume":"17","author":"Bryan-Marrugo","year":"2015","journal-title":"Med. Univ."},{"key":"10.1016\/j.cbi.2025.111597_bib10","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1128\/AAC.11.6.946","article-title":"Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate","volume":"11","author":"Eriksson","year":"1977","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cbi.2025.111597_bib11","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1016\/j.bmcl.2017.08.029","article-title":"The discovery of IDX21437: design, synthesis and antiviral evaluation of 2'-alpha-chloro-2'-beta-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors","volume":"27","author":"Alexandre","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.cbi.2025.111597_bib12","doi-asserted-by":"crossref","first-page":"12633","DOI":"10.1016\/S0021-9258(18)99923-0","article-title":"Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells","volume":"269","author":"Gao","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2025.111597_bib13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbrc.2012.03.122","article-title":"DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells","volume":"421","author":"Saiki","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cbi.2025.111597_bib14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.critrevonc.2016.01.015","article-title":"Improving nucleoside analogs via lipid conjugation: is fatter any better?","volume":"100","author":"Alexander","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.cbi.2025.111597_bib15","doi-asserted-by":"crossref","first-page":"10400","DOI":"10.1021\/acs.jmedchem.6b00523","article-title":"Nucleoside phosphate and phosphonate prodrug clinical candidates","volume":"59","author":"Thornton","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111597_bib16","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1021\/acs.jmedchem.7b00734","article-title":"The ProTide prodrug technology: from the concept to the clinic","volume":"61","author":"Mehellou","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111597_bib17","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/cmdc.200900289","article-title":"Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells","volume":"4","author":"Mehellou","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.cbi.2025.111597_bib18","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1128\/AAC.49.5.1898-1906.2005","article-title":"Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue","volume":"49","author":"Lee","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cbi.2025.111597_bib19","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1128\/AAC.01184-07","article-title":"The mechanism of action of beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine involves a second metabolic pathway leading to beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine 5'-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase","volume":"52","author":"Murakami","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cbi.2025.111597_bib20","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111597_bib21","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1158\/1078-0432.CCR-21-1652","article-title":"The novel nucleoside analogue ProTide NUC-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human phase I clinical trial","volume":"27","author":"Schwenzer","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cbi.2025.111597_bib22","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1016\/j.bmc.2010.03.041","article-title":"Discovery of GS-9131: design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148","volume":"18","author":"Mackman","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111597_bib23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1128\/AAC.01834-15","article-title":"Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors","volume":"60","author":"Birkus","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cbi.2025.111597_bib24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1128\/AAC.00968-06","article-title":"Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131","volume":"51","author":"Birkus","year":"2007","journal-title":"Antimicrob Agents Ch"},{"key":"10.1016\/j.cbi.2025.111597_bib25","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1021\/jm9007856","article-title":"The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition","volume":"52","author":"Derudas","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111597_bib26","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/tx050072+","article-title":"Stereoselective hydrolysis of pyrethroid-like fluorescent substrates by human and other mammalian liver carboxylesterases","volume":"18","author":"Huang","year":"2005","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2025.111597_bib27","doi-asserted-by":"crossref","first-page":"34337","DOI":"10.1074\/jbc.M110.161802","article-title":"Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977","volume":"285","author":"Murakami","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2025.111597_bib28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1039\/C8OB02870B","article-title":"Reactive cyclic intermediates in the ProTide prodrugs activation: trapping the elusive pentavalent phosphorane","volume":"17","author":"Prochazkova","year":"2019","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.cbi.2025.111597_bib29","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1021\/acs.biochem.4c00176","article-title":"Regiochemical analysis of the ProTide activation mechanism","volume":"63","author":"Glockzin","year":"2024","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2025.111597_bib30","article-title":"Anticancer effect of chlorambucil enhanced by chiral phthalidyl promoiety","volume":"20","author":"Zhang","year":"2023","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.cbi.2025.111597_bib31","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111597_bib32","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.00128-15","article-title":"Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy","volume":"59","author":"Murakami","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cbi.2025.111597_bib33","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1021\/acsptsci.3c00050","article-title":"Cell-dependent activation of ProTide prodrugs and its implications in antiviral studies","volume":"6","author":"Liu","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.cbi.2025.111597_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00620-18","article-title":"Nucleotide prodrug containing a nonproteinogenic amino acid to improve oral delivery of a hepatitis C virus treatment","volume":"62","author":"Feng","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cbi.2025.111597_bib35","doi-asserted-by":"crossref","first-page":"7656","DOI":"10.1021\/acs.orglett.0c02848","article-title":"Expanding access to Remdesivir via an improved pyrrolotriazine synthesis: supply centered synthesis","volume":"22","author":"Paymode","year":"2020","journal-title":"Org. Lett."},{"key":"10.1016\/j.cbi.2025.111597_bib36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/acs.oprd.1c00071","article-title":"Facile and scalable methodology for the pyrrolo[2,1-f][1,2,4]triazine of Remdesivir","volume":"26","author":"Roy","year":"2022","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.cbi.2025.111597_bib37","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1021\/acs.oprd.1c00026","article-title":"Synthesis of Rovafovir etalafenamide (Part IV): evolution of the synthetic process to the fluorinated nucleoside fragment","volume":"25","author":"Siler","year":"2021","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.cbi.2025.111597_bib38","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1021\/ja502205q","article-title":"A general and enantioselective approach to pentoses: a rapid synthesis of PSI-6130, the nucleoside core of sofosbuvir","volume":"136","author":"Peifer","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.cbi.2025.111597_bib39","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1021\/acs.oprd.0c00172","article-title":"Development of a large-scale cyanation process using continuous flow chemistry en route to the synthesis of Remdesivir","volume":"24","author":"Vieira","year":"2020","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.cbi.2025.111597_bib40","doi-asserted-by":"crossref","first-page":"19356","DOI":"10.1021\/acsomega.1c03082","article-title":"Evolution of the synthesis of Remdesivir. Classical approaches and most recent advances","volume":"6","author":"Vargas","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.cbi.2025.111597_bib41","first-page":"95","article-title":"Discovery and chemical development of Adafosbuvir, a nucleoside phosphoramidate prodrug for the treatment of hepatitis C infection","volume":"vol. 4","author":"Cao","year":"2022"},{"key":"10.1016\/j.cbi.2025.111597_bib42","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1021\/acs.oprd.0c00310","article-title":"Improvement of the C-glycosylation step for the synthesis of Remdesivir","volume":"24","author":"Xue","year":"2020","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.cbi.2025.111597_bib43","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1021\/acs.oprd.0c00428","article-title":"Synthesis of Rovafovir etalafenamide (Part III): evolution of the synthetic process to the phosphonamidate fragment","volume":"25","author":"Ambrosi","year":"2021","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.cbi.2025.111597_bib44","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1021\/jm400201a","article-title":"Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients","volume":"57","author":"Cho","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111597_bib45","doi-asserted-by":"crossref","first-page":"8311","DOI":"10.1021\/jo201492m","article-title":"Synthesis of diastereomerically pure nucleotide phosphoramidates","volume":"76","author":"Ross","year":"2011","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.cbi.2025.111597_bib46","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1021\/acs.orglett.7b00469","article-title":"Mechanism-based solution to the ProTide synthesis problem: selective access to sofosbuvir, acelarin, and INX-08189","volume":"19","author":"Simmons","year":"2017","journal-title":"Org. Lett."},{"key":"10.1016\/j.cbi.2025.111597_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/catal10121420","article-title":"Biocatalysis in the Swiss manufacturing environment","volume":"10","author":"Hecht","year":"2020","journal-title":"Catalysts"},{"key":"10.1016\/j.cbi.2025.111597_bib48","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1039\/D0CS00763C","article-title":"Biocatalytic routes to anti-viral agents and their synthetic intermediates","volume":"50","author":"Slagman","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.cbi.2025.111597_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/catal9040355","article-title":"Synthesis of ribavirin, tecadenoson, and cladribine by enzymatic transglycosylation","volume":"9","author":"Rabuffetti","year":"2019","journal-title":"Catalysts"},{"key":"10.1016\/j.cbi.2025.111597_bib50","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.tetasy.2009.02.006","article-title":"A practical synthesis of (2)-3,5-di- -benzoyl-2-fluoro-2-C-methyl-D-ribono-\u03b3-lactone","volume":"20","author":"Zhang","year":"2009","journal-title":"Tetrahedron-Asymmetr"},{"key":"10.1016\/j.cbi.2025.111597_bib51","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3762\/bjoc.14.36","article-title":"Continuous multistep synthesis of 2-(azidomethyl)oxazoles","volume":"14","author":"Rossa","year":"2018","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.cbi.2025.111597_bib52","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/bi001548l","article-title":"Structural determinants of the substrate and stereochemical specificity of phosphotriesterase","volume":"40","author":"Chen-Goodspeed","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2025.111597_bib53","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1021\/bi982204m","article-title":"Stereochemical constraints on the substrate specificity of phosphotriesterase","volume":"38","author":"Hong","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2025.111597_bib54","doi-asserted-by":"crossref","first-page":"19659","DOI":"10.1016\/S0021-9258(19)47164-0","article-title":"Purification and properties of the phosphotriesterase from Pseudomonas diminuta","volume":"264","author":"Dumas","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2025.111597_bib55","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/bi001549d","article-title":"Enhancement, relaxation, and reversal of the stereoselectivity for phosphotriesterase by rational evolution of active site residues","volume":"40","author":"Chen-Goodspeed","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2025.111597_bib56","doi-asserted-by":"crossref","first-page":"15892","DOI":"10.1021\/ja0658618","article-title":"Resolution of chiral phosphate, phosphonate, and phosphinate esters by an enantioselective enzyme library","volume":"128","author":"Nowlan","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.cbi.2025.111597_bib57","doi-asserted-by":"crossref","first-page":"7973","DOI":"10.1021\/bi00025a002","article-title":"Three-dimensional structure of the binuclear metal center of phosphotriesterase","volume":"34","author":"Benning","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2025.111597_bib58","doi-asserted-by":"crossref","first-page":"7988","DOI":"10.1021\/bi101058z","article-title":"Structural determinants for the stereoselective hydrolysis of chiral substrates by phosphotriesterase","volume":"49","author":"Tsai","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2025.111597_bib59","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.enzmictec.2005.04.004","article-title":"Stereospecificity in the enzymatic hydrolysis of cyclosarin (GF)","volume":"37","author":"Harvey","year":"2005","journal-title":"Enzym. Microb. Technol."},{"key":"10.1016\/j.cbi.2025.111597_bib60","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1021\/bi00244a010","article-title":"Limits of diffusion in the hydrolysis of substrates by the phosphotriesterase from Pseudomonas diminuta","volume":"30","author":"Caldwell","year":"1991","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2025.111597_bib61","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1021\/acs.biochem.5b00629","article-title":"Variants of phosphotriesterase for the enhanced detoxification of the chemical warfare agent VR","volume":"54","author":"Bigley","year":"2015","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2025.111597_bib62","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1021\/bi300811t","article-title":"Enzymes for the homeland defense: optimizing phosphotriesterase for the hydrolysis of organophosphate nerve agents","volume":"51","author":"Tsai","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2025.111597_bib63","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1021\/acs.biochem.1c00361","article-title":"Substrate analogues for the enzyme-catalyzed detoxification of the organophosphate nerve agents-sarin, soman, and cyclosarin","volume":"60","author":"Bigley","year":"2021","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2025.111597_bib64","doi-asserted-by":"crossref","first-page":"7978","DOI":"10.1021\/bi101056m","article-title":"Stereoselective hydrolysis of organophosphate nerve agents by the bacterial phosphotriesterase","volume":"49","author":"Tsai","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2025.111597_bib65","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1021\/ja017840d","article-title":"Enzymatic synthesis of chiral organophosphothioates from prochiral precursors","volume":"124","author":"Li","year":"2002","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.cbi.2025.111597_bib66","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1021\/acs.biochem.0c00089","article-title":"Stereoselective Formation of multiple reaction products by the phosphotriesterase from Sphingobium sp. TCM1","volume":"59","author":"Bigley","year":"2020","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2025.111597_bib67","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1021\/acs.biochem.9b00530","article-title":"Enzyme-catalyzed kinetic resolution of chiral precursors to antiviral prodrugs","volume":"58","author":"Xiang","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2025.111597_bib68","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1021\/acs.biochem.9b00097","article-title":"Overcoming the challenges of enzyme evolution to adapt phosphotriesterase for V-agent decontamination","volume":"58","author":"Bigley","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2025.111597_bib69","doi-asserted-by":"crossref","first-page":"10426","DOI":"10.1021\/ja402832z","article-title":"Enzymatic neutralization of the chemical warfare agent VX: evolution of phosphotriesterase for phosphorothiolate hydrolysis","volume":"135","author":"Bigley","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.cbi.2025.111597_bib70","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1021\/acs.biochem.0c00591","article-title":"A chemoenzymatic synthesis of the (RP)-Isomer of the antiviral prodrug Remdesivir","volume":"59","author":"Bigley","year":"2020","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2025.111597_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2024.1446566","article-title":"Improving stereoselectivity of phosphotriesterase (PTE) for kinetic resolution of chiral phosphates","volume":"12","author":"Jaito","year":"2024","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.cbi.2025.111597_bib72","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cbi.2025.111597_bib73","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s13238-020-00718-6","article-title":"Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids","volume":"11","author":"Zhao","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.cbi.2025.111597_bib74","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1021\/jm00038a015","article-title":"Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA)","volume":"37","author":"Starrett","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111597_bib75","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1021\/acs.oprd.1c00059","article-title":"Synthesis of Rovafovir etalafenamide (Part I): active pharmaceutical ingredient process development, scale-up, and impurity control strategy","volume":"25","author":"Standley","year":"2021","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.cbi.2025.111597_bib76","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1021\/acs.oprd.3c00070","article-title":"Practical synthesis of tenofovir alafenamide fumarate inspired by new retrosynthetic disconnection featuring a novel carbon-phosphorus bond construction methodology","volume":"27","author":"Liu","year":"2023","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.cbi.2025.111597_bib77","doi-asserted-by":"crossref","first-page":"10904","DOI":"10.1021\/bi960663m","article-title":"Metal-substrate interactions facilitate the catalytic activity of the bacterial phosphotriesterase","volume":"35","author":"Hong","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2025.111597_bib78","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1021\/acs.biochem.5b01144","article-title":"Interrogation of the substrate profile and catalytic properties of the phosphotriesterase from Sphingobium sp. strain TCM1: an enzyme capable of hydrolyzing organophosphate flame retardants and plasticizers","volume":"54","author":"Xiang","year":"2015","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2025.111597_bib79","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade9582","article-title":"An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression","volume":"8","author":"Das","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.cbi.2025.111597_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25690-5","article-title":"Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles","volume":"12","author":"Cobb","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cbi.2025.111597_bib81","doi-asserted-by":"crossref","first-page":"10825","DOI":"10.1073\/pnas.88.23.10825","article-title":"Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex","volume":"88","author":"Katz","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cbi.2025.111597_bib82","doi-asserted-by":"crossref","first-page":"8371","DOI":"10.1039\/C8CC04708A","article-title":"ProTide generated long-acting abacavir nanoformulations","volume":"54","author":"Lin","year":"2018","journal-title":"Chem. Commun."},{"key":"10.1016\/j.cbi.2025.111597_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119476","article-title":"A long acting nanoformulated lamivudine ProTide","volume":"223","author":"Smith","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.cbi.2025.111597_bib84","article-title":"A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice","volume":"28","author":"Wang","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.cbi.2025.111597_bib85","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1021\/jacs.3c10086","article-title":"Modular design platform for activatable fluorescence probes targeting carboxypeptidases based on ProTide chemistry","volume":"146","author":"Kuriki","year":"2024","journal-title":"J. Am. Chem. Soc."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279725002273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279725002273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:18:09Z","timestamp":1778876289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279725002273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":85,"alternative-id":["S0009279725002273"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2025.111597","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of phosphotriesterase in the synthesis of enantiomerically pure ProTide prodrugs","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2025.111597","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111597"}}